Inhalation Sciences Sweden AB (ISAB) has secured new service orders totalling approximately SEK 350,000 for its proprietary PreciseInhale® platform. The orders originate from established customers within the global pharmaceutical industry.
The repeat business underlines the sustained commercial relevance of ISAB's technology in pharmaceutical inhalation research. Both clients have maintained an active collaboration with ISAB over an extended period, integrating PreciseInhale® as part of their ongoing research workflows.
Manoush Masarrat, CEO of Inhalation Sciences, comments:
"It is encouraging to see continued demand from clients who have worked with our platform over many years. Repeat orders like these reflect not only the technical robustness of PreciseInhale® but also the strong relationships we build with our customers. We remain committed to supporting their R&D goals and to advancing the science of inhalation drug delivery."
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.